|Exchange:||New York Stock Exchange|
|Novo Nordisk is a healthcare company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company operates in two business segments, diabetes care and biopharmaceuticals. The diabetes care segment covers insulin’s, GLP-1, other protein-related products and projects such as glucagon and protein-related delivery systems, obesity and oral anti-diabetic drugs. The biopharmaceuticals segment covers the therapy areas of hemophilia, growth hormone therapy, hormone replacement therapy and inflammation. The company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.|
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.